assessing elacestrant in ctdna-positive patients with er breast cancer
Published 2 years ago • 214 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
1:36
ctdna assay for detection of recurrent disease in patients with early-stage breast cancer
-
2:15
treat ctdna: early elacestrant intervention for er /her2- breast cancer
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
2:06
elaine 1: esr1 mutations in ctdna from er /her2- mbc treated with lasofoxifene or fulvestrant
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
2:29
window of opportunity elipse trial: elacestrant in postmenopausal women with er her2-/ early bc
-
3:24
elacestrant shows improved pfs in patients with er-positive/her2-negative metastatic breast cancer
-
0:52
fragmentomic analysis of a ctdna discriminates er status in metastatic breast cancer
-
0:55
cambria-1: camizestrant vs standard endocrine therapy in breast cancer
-
1:01
what emerald phase iii trial could mean for breast cancer patients | virginia kaklamani, md
-
2:35
what does the future hold for serds in er breast cancer?
-
0:53
final results of the phase 3 data trial assessing aromatase inhibition in hr breast cancer
-
2:37
elacestrant: a new weapon against advanced estrogen receptor-positive breast cancer
-
4:39
serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
-
16:11
ctdna in breast cancer | 2023 coeds discussion series fort lauderdale
-
0:50
fda approves elacestrant (orserdu) for er-positive, her2-negative, esr1-mutated breast cancer
-
1:24
detection of ctdna post neoadjuvant chemo is associated with disease relapse in early breast cancer
-
7:08
selective oestrogen receptor degraders as treatment for er positive/her2 negative advanced/metas...